招股书显示，泰诺麦博是一家面向全球市场、致力于血液制品替代疗法的创新生物制药企业。公司 以"创造临床价值"为导向，秉持差异化创新和竞争战略，致力于全人源单抗新药的开发、制造、商业化 及全球特异性血液制品的潜在替代，以满足广泛的临床需求，造福病患。 值得一提的是，泰诺麦博系科创板第五套上市标准重启后首家获得受理的企业。 北京商报讯（记者 丁宁）7月31日晚间，上交所官网显示，珠海泰诺麦博制药股份有限公司（以下简 称"泰诺麦博"）科创板IPO获得受理。 公司此次IPO拟募集资金15亿元，用于新药研发项目、抗体生产基地扩建项目和补充营运资金项目。 ...

Core Viewpoint - Beijing Angrui Microelectronics Technology Co., Ltd. is progressing with its IPO on the Sci-Tech Innovation Board, having recently responded to the first round of inquiry letters from the Shanghai Stock Exchange [1] Financial Performance - The company reported projected revenues of approximately 0.923 billion, 1.695 billion, and 2.101 billion yuan for the years 2022, 2023, and 2024 respectively [1] - Corresponding net profits are expected to be around -0.29 billion, -0.45 billion, and -0.0647092 billion yuan for the same years [1] IPO Details - Angrui Micro plans to raise approximately 2.067 billion yuan through the IPO, which will be allocated to projects including the development and industrialization of 5G RF front-end chips and modules, RF SoC development, and the construction of its headquarters and R&D center [1] Regulatory Inquiry - The first round of inquiry letters raised questions regarding the company's products, market position, and sustainability of operations [1]

Core Viewpoint - Baiaosaitu (Beijing) Pharmaceutical Technology Co., Ltd. is undergoing an IPO process on the Sci-Tech Innovation Board, revealing a significant reduction in dedicated R&D personnel and a decrease in fundraising amount from 18.93 billion to 11.85 billion [1][5]. Group 1: R&D Personnel Changes - The number of dedicated R&D personnel at Baiaosaitu has drastically decreased from 58 at the end of 2022 to 5 by the end of 2024 [1][3]. - The total number of R&D personnel, including both dedicated and part-time, has also declined from 627 in 2022 to 337 in 2024 [3][4]. - The company has clarified that all personnel involved in innovative drug R&D are dedicated, while those in preclinical CRO services are part-time, aligning with industry norms [4]. Group 2: Fundraising Adjustments - The company has revised its fundraising target down to 11.85 billion, with allocations for various projects including early drug development services and antibody drug research [5]. - The initial fundraising amount was set at 18.93 billion, with the same project allocations, indicating a significant reduction of over 7 billion [5]. - The adjustments in fundraising may reflect changes in the company's operational status or market conditions, necessitating a reassessment of funding needs [5]. Group 3: Financial Performance - Baiaosaitu is projected to turn a profit in 2024 after consecutive years of losses, with revenues increasing from approximately 5.34 billion in 2022 to 9.8 billion in 2024 [5]. - The net profit attributable to the company is expected to shift from losses of 6.02 billion and 3.83 billion in 2022 and 2023, respectively, to a profit of approximately 335.42 million in 2024 [5].

Core Viewpoint - The China Securities Regulatory Commission has accepted the application for the initial public offering (IPO) and listing guidance of China Electronics Technology Group Corporation Si Yi Technology Co., Ltd., with the filing date set for July 23, 2025, and the guiding institution being Guotai Junan Securities [1] Group 1: Company Background - Si Yi Technology was established in 2015 and specializes in the research, development, manufacturing, and sales of electronic measurement instruments, with main products including complete machines, testing systems, and components [4] - The company previously applied for an IPO on the Sci-Tech Innovation Board in December 2022, which was accepted by the Shanghai Stock Exchange, with the sponsoring institution being CITIC Securities [3][4] Group 2: Financial Performance - The company's revenue for the years 2020, 2021, and 2022 was 1.2508 billion, 1.5131 billion, and 1.9492 billion yuan respectively, while net profits were 119.04 million, 191.33 million, and 227.87 million yuan [5] - The non-recurring net profits for the same years were 67.54 million, 152.27 million, and 198.04 million yuan, indicating a steady growth trend [5] - Government subsidies accounted for a significant portion of the total profit, with proportions of 46.54%, 22.59%, and 17.18% for the respective years [5] Group 3: IPO Fund Utilization - The previous IPO fundraising plan included projects such as the renovation and expansion of high-end electronic measurement instrument production lines, R&D and industrialization of new-generation mobile communication testing, and the establishment of a technology innovation center, with a total intended investment of 1.206 billion yuan [6] - The total planned investment for these projects was 1.2055 billion yuan, with specific allocations for each project [6] Group 4: Shareholding Structure - China Electronics Technology Group Corporation directly holds 41.74 million shares of Si Yi Technology, accounting for 50.54% of the total share capital, making it the controlling shareholder and actual controller of the company [6]

Core Viewpoint - Nanjing Qinheng Microelectronics Co., Ltd. (referred to as "Qinheng Micro") has made progress in its A-share IPO application, entering the inquiry stage, supported by steady revenue and profit growth during the reporting period [1][4]. Group 1: Financial Performance - Qinheng Micro's revenue and net profit have shown consistent growth from 2022 to 2024, with revenues of approximately 238 million yuan, 308 million yuan, and 397 million yuan, and corresponding net profits of approximately 59.1 million yuan, 72.4 million yuan, and 104 million yuan [4]. - The company's gross profit margins for its main business were 63.32%, 58.82%, and 57.51% from 2022 to 2024, indicating a gradual decline due to changes in product sales structure [5]. Group 2: Customer Base and Market Position - Qinheng Micro has a relatively low customer concentration, with sales to its top five customers accounting for 10.28%, 15.05%, and 14.15% of total revenue from 2022 to 2024, respectively [4]. - The company focuses on the long-tail market in industrial and automotive sectors, which allows for a diverse customer base and mitigates the impact of cyclical fluctuations in specific industries [5]. Group 3: Research and Development - The company's R&D expenses were 60.9 million yuan, 67.7 million yuan, and 76.2 million yuan from 2022 to 2024, representing 25.54%, 22.01%, and 19.2% of revenue, respectively, indicating a decrease in R&D expense ratio due to faster revenue growth [6]. - Qinheng Micro plans to raise approximately 932 million yuan through its IPO to invest in various chip development projects, which is expected to significantly increase R&D spending in the future [6]. Group 4: Ownership and Governance - The controlling shareholder, Wang Chunhua, holds over 90% of the voting rights, with Qinheng directly owning 56.04% and Wang holding 28.46%, leading to potential concerns about governance and decision-making power [7]. - Despite the high concentration of control, the company claims to have established a governance structure that ensures checks and balances among its board and committees, aiming to mitigate risks associated with concentrated ownership [7].

Core Insights - The article celebrates the 6th anniversary of the Sci-Tech Innovation Board (STAR Market) and provides statistics on the number of listed companies and their IPO intermediaries [1] Group 1: IPO Statistics - As of now, there are 589 listed companies on the STAR Market, with the number of IPOs per year as follows: 70 in 2019, 143 in 2020, 162 in 2021, 124 in 2022, 67 in 2023, 15 in 2024, and 8 from 2025 to present [1] - The intermediaries involved in these IPOs include 53 securities firms, 67 law firms, and 29 accounting firms [1] Group 2: Top IPO Sponsors - The most active IPO sponsor representative is Zhao Liang from CITIC Securities, with 6 projects [2] - Wang Bin, also from CITIC Securities, follows with 5 projects, while 47 other representatives have completed 3 or more projects [2][3] Group 3: Top Lawyers - The leading IPO lawyer is Wang Li from Shanghai Jintiancheng, with 11 projects, followed by Shen Cheng from the same firm with 10 projects, and Shi Tiejun from Beijing Junhe with 8 projects [5] Group 4: Top Accountants - The top IPO accountant is Wang Qiang from Tianjian, with 8 projects, followed by Zhang Songbai and Wang Na from Lixin, with 7 and 6 projects respectively [6]

Core Viewpoint - Shandong Dongyue Future Hydrogen Energy Materials Co., Ltd. (Future Materials) has restarted its IPO process and submitted its application to the Shanghai Stock Exchange, marking its third attempt to go public after previous failures due to various issues. The company aims to raise 2.446 billion yuan for R&D, expansion, and working capital, with a significant portion allocated for production expansion despite rising inventory levels and declining turnover rates [1][2][3]. Financial Performance - Future Materials has experienced fluctuating financial performance, with revenues increasing initially but then declining. For the years 2022 to 2024, the company reported revenues of 524 million yuan, 721 million yuan, and 640 million yuan, respectively, with net profits of 143 million yuan, 230 million yuan, and 165 million yuan. The revenue for 2024 is projected to decrease by 11.23%, and net profit is expected to drop by 28.26% [2][3][4]. Product Pricing and Market Pressure - The company faces market price pressures for several products, particularly the perfluorinated proton exchange membrane, which saw its price drop from 909.68 yuan per square meter in 2022 to 655.41 yuan in 2024, a decrease of 27.95%. The overall revenue contribution from high-performance fluorinated functional membranes has also declined from 93.99% in 2022 to 60.20% in 2024 [4][5][6]. Key Customer Relationships - Future Materials has established a significant partnership with Dalian Rongke, a leading vanadium flow battery company, which has become its largest customer, contributing 66.45% of the sales revenue from perfluorinated proton exchange membranes in 2024. This relationship is crucial for maintaining stable order sources amid declining overall revenue [6][7][8]. Inventory and Production Capacity - The company has a production capacity of 625,000 square meters for perfluorinated proton exchange membranes, with a utilization rate of 45.25% and a sales-to-production ratio of 84.98%. Future Materials plans to invest 559 million yuan in expanding its production capacity significantly [11][12]. Related Party Transactions - Future Materials has frequent related party transactions, with significant sales and purchases involving its major customer and supplier, Dongyue Fluorosilicon Technology Group. The company has taken steps to reduce the scale of these transactions by engaging third-party suppliers [14][16][17]. Control and Ownership Structure - The ownership structure of Future Materials is complex, with control shifting among shareholders over the years. As of now, Zhang Jianhong is the controlling shareholder, holding the highest voting rights, while the previous controlling parties have seen their influence diminish due to financial difficulties and restructuring [20][22][24].

Core Viewpoint - Hengrun Dazheng, a biotech company focused on immune cell therapy, is attempting to go public on the Sci-Tech Innovation Board despite being unprofitable and facing significant financial losses. The company has not yet commercialized any products and is at risk of delisting if it fails to meet financial performance criteria post-IPO [1][2][5]. Financial Performance - Hengrun Dazheng has reported substantial losses over the past three years, with net losses of CNY 274 million, CNY 283 million, and CNY 188 million from 2022 to 2024. As of the end of 2024, the cumulative undistributed profits stand at -CNY 904 million [2][3]. - The company has incurred high R&D expenses, amounting to CNY 242 million, CNY 256 million, and CNY 152 million from 2022 to 2024, contributing to its financial losses [3]. - Cash flow from operating activities has been negative, with net cash flows of -CNY 209 million, -CNY 226 million, and -CNY 141 million during the same period, leading to a significant reduction in liquid assets [3]. Liquidity and Solvency - Hengrun Dazheng's liquidity ratios, including current and quick ratios, have been declining, indicating insufficient debt repayment capacity. The debt-to-asset ratio has increased significantly, reaching 84.76% by the end of 2024, which is considerably higher than the average of comparable companies [3][4]. Product Development and Market Position - The company is developing a pipeline of 11 projects, including CAR-T and CAR-NK therapies, with the most advanced products HR001 and HR003 expected to enter the market by 2025. However, these products face competition from at least six already approved CAR-T therapies in China [7][8]. - The efficacy and safety of Hengrun Dazheng's core products have been questioned, with HR001 showing an overall response rate (ORR) of 68%, which is lower than competitors, and HR003 showing an ORR of 86%, also below market standards [9][10]. IPO and Valuation - Hengrun Dazheng plans to issue up to 50 million shares, aiming to raise CNY 2.539 billion for R&D and operational expenses. The estimated post-IPO valuation exceeds CNY 10 billion, which is considered high given the competitive landscape and the company's current lack of revenue [11].

Core Viewpoint - Yushu Technology is gaining significant attention regarding its potential IPO, with speculation about its listing location, primarily focusing on the Sci-Tech Innovation Board (STAR Market) in China [1][2][4]. Group 1: Company Overview - Yushu Technology is recognized as a leading humanoid robotics company in China, with increasing visibility through various public events and media coverage [2]. - The company has completed its shareholding reform, changing its name to "Hangzhou Yushu Technology Co., Ltd." which is seen as a precursor to the IPO process [4]. - Yushu Technology has reportedly achieved profitability for five consecutive years, with revenues exceeding 1 billion yuan [10][11]. Group 2: IPO Speculation - There is ongoing speculation about whether Yushu Technology will choose to list on the A-share market or the Hong Kong stock market, with A-shares being viewed as a more favorable environment for tech companies [5][9]. - The company has completed a Series C financing round, attracting investments from major players like Tencent, Alibaba, and Geely Capital, indicating strong investor interest [4][10]. - The current IPO environment for A-shares has slowed down, while many tech companies are opting for listings in Hong Kong, leading to discussions about Yushu Technology's potential listing strategy [4][5]. Group 3: Market Context - The STAR Market has recently undergone reforms aimed at attracting high-tech companies, which may benefit Yushu Technology if it decides to pursue this route [10][11]. - Investors believe that Yushu Technology's unique positioning in the humanoid robotics sector aligns well with the STAR Market's focus on hard technology [10][11]. - The timeline for Yushu Technology's IPO could be influenced by the completion of necessary preparatory work, with a potential listing by the end of 2025 if the process is expedited [5][11].

Core Viewpoint - Xiamen Youxun Chip Co., Ltd. has been accepted for IPO on the Sci-Tech Innovation Board, focusing on the research, design, and sales of optical communication front-end transceiver chips, positioning itself as a "national manufacturing single champion" in the optical communication field [2]. Financial Performance - The company reported total assets of 8.174 billion yuan for 2024, up from 5.874 billion yuan in 2023 and 4.228 billion yuan in 2022 [3]. - The net profit for 2024 is projected at 778.664 million yuan, an increase from 720.835 million yuan in 2023, but a decrease from 813.984 million yuan in 2022 [3]. - Operating revenue is expected to rise to 4.105 billion yuan in 2024, compared to 3.131 billion yuan in 2023 and 3.390 billion yuan in 2022 [3]. - The company's debt-to-asset ratio is projected to decrease to 10.99% in 2024 from 13.64% in 2023 and 21.09% in 2022 [3]. - R&D investment as a percentage of operating revenue is 19.10% for 2024, slightly down from 21.09% in 2023 and 21.14% in 2022 [3]. Shareholding Structure - The shareholding structure is relatively dispersed, with no single shareholder holding more than 30% of voting rights, indicating no controlling shareholder [5]. - The actual controllers of the company are Ke Binglan and Ke Tenglong, who collectively control 27.13% of the voting rights [5]. Management Team - Ke Binglan, the chairman and general manager, has a long history in various managerial roles and has been with the company since its inception [6]. - Ke Tenglong, the general manager, has been with the company since 2014 and has held several key positions leading up to his current role [7]. - The combined salary for Ke Binglan and Ke Tenglong in 2024 is projected to be 2.7898 million yuan [8].